Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 13/20 | 0.76 |
| ▸ | GABRB2 | P47870 | 13/20 | 0.76 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.76 |
| ▸ | CNR2 | P34972 | 6/20 | 0.76 |
| ▸ | CNR1 | P21554 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | GAA | P10253 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.76 |
| ▸ | RXRA | P19793 | 1/20 | 0.76 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.76 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.76 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.76 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.76 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7785437 | 0.89 | GABRA1 (0.76) | GABRA1GABRB2ALOX5CNR2CNR1 | |
| SCHEMBL29443445 | 0.89 | GABRA1 (0.76) | GABRA1GABRB2ALOX5CNR2CNR1 | |
| SCHEMBL18793822 | 0.89 | GABRA1 (0.81) | GABRA1GABRB2ALOX5CNR2CNR1 | |
| Honokiol SCHEMBL16011724 | 0.87 | GABRA1 (1.00) | GABRA1GABRB2ALOX5CNR2CNR1 | |
| Honokiol SCHEMBL29363985 | 0.87 | GABRA1 (1.00) | GABRA1GABRB2ALOX5CNR2CNR1 | |
| Honokiol SCHEMBL30008303 | 0.87 | GABRA1 (1.00) | GABRA1GABRB2ALOX5CNR2CNR1 | |
| Honokiol SCHEMBL29384099 | 0.87 | GABRA1 (1.00) | GABRA1GABRB2ALOX5CNR2CNR1 | |
| Honokiol SCHEMBL133034 | 0.87 | GABRA1 (1.00) | GABRA1GABRB2ALOX5CNR2CNR1 | |
| Magnolol SCHEMBL527731 | 0.85 | GABRA1 (0.97) | GABRA1GABRB2ALOX5CNR2CNR1 | |
| SCHEMBL12319404 | 0.85 | ALOX5 (1.00) | GABRA1GABRB2ALOX5CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303788-A1 | METHOD OF PRODUCING BIPHENOLIC COMPOUND, NOVEL BIPHENYL COMPOUND AND SYNTHESIS METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE | TZU CHI UNIVERSITY (TW) | 2013-11-14 | — | — | US | claimed |
| EP-0991614-A1 | SYNTHESIS OF DIHYDROHONOKIOL COMPOSITIONS | Board of Regents, The University of Texas System (US) | 2000-04-12 | — | — | EP | claimed |
| WO-1999000346-A1 | SYNTHESIS OF DIHYDROHONOKIOL COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1999-01-07 | — | — | WO | claimed |
| EP-3364957-B1 | IMPROVED SYNTHESIS OF HONOKIOL | COLGATE PALMOLIVE CO (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2017070568-A1 | IMPROVED SYNTHESIS OF HONOKIOL | COLGATE-PALMOLIVE COMPANY (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170113989-A1 | SYNTHESIS OF HONOKIOL | COLGATE-PALMOLIVE COMPANY | 2017-04-27 | — | — | US | disclosed |
| US-20170113989-A1 | SYNTHESIS OF HONOKIOL | COLGATE-PALMOLIVE COMPANY | 2017-04-27 | — | — | US | disclosed |
| US-20130303788-A1 | METHOD OF PRODUCING BIPHENOLIC COMPOUND, NOVEL BIPHENYL COMPOUND AND SYNTHESIS METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE | TZU CHI UNIVERSITY (TW) | 2013-11-14 | — | — | US | disclosed |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| EP-1140756-A2 | SYNTHESIS OF DIHYDROHONOKIOL COMPOSITIONS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040532-A2 | SYNTHESIS OF DIHYDROHONOKIOL COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-07-13 | — | — | WO | disclosed |
| EP-0991614-A1 | SYNTHESIS OF DIHYDROHONOKIOL COMPOSITIONS | Board of Regents, The University of Texas System (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999036380-A1 | ANXIOLYTIC AGENTS CONTAINING BIPHENYL DERIVATIVES AS THE ACTIVE INGREDIENT | TSUMURA & CO. (JP) | 1999-07-22 | — | — | WO | disclosed |
| WO-1999000346-A1 | SYNTHESIS OF DIHYDROHONOKIOL COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303788-A1 | METHOD OF PRODUCING BIPHENOLIC COMPOUND, NOVEL BIPHENYL COMPOUND AND SYNTHESIS METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE | PARK7, DBH, SNCA | GABRA1 625/4885GABRB2 392/4885ALOX5 79/4885 |
| US-20170113989-A1 | SYNTHESIS OF HONOKIOL | UGT2B7, UGT1A7, DHCR7 | GABRA1 395/4885GABRB2 320/4885ALOX5 374/4885 |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | CCNK, CDK3, CCNO | GABRA1 4042/4885GABRB2 4180/4885ALOX5 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.